December 2, 2025 Sweden
Den 27 november samlades ledande aktörer i life science-branschen för att diskutera hur hållbarhetsarbete och innovation kan stärka både konkurrenskraft och samhällsresiliens. Lif lyfte fram hur medlemsföretagen lever upp till åtagandena i hållbarhetsmanifestet – inklusive färdplanen för fossilfri konkurrenskraft. I anslutning till konferensen presenterades flera konkreta exempel på hållbar produktion, bland dem Diamyd Medicals anläggning i Umeå, som med hjälp av Cytivas single-use-teknik minskar både vatten- och energiförbrukning. Läs artikeln härSe konferensen här
|
November 28, 2025 Sweden
Bolagspresentation av vd Ulf Hannelius från Stora Aktiedagarna i Stockholm den 27 november 2025. Aktiedagarna arrangeras av Aktiespararna.
|
November 19, 2025 USA
On October 25-27 2025 Breakthrough T1D gathered leading experts from academia, biotech and pharma to discuss how disease-modifying therapies can change the course of type 1 diabetes from the earliest stages. This recording from one of the panel session highlighted progress from Stage 2 treatments like teplizumab toward new applications in Stage 3, as well as next-generation immunotherapies from Sanofi, Eli Lilly and Diamyd Medical targeting different immune pathways and specific genetic subgroups. A central theme was the need to treat T1D as an autoimmune disease, not only a glucose/insulin problem, and to secure regulatory acceptance of C-peptide as a key endpoint, while also addressing two urgent challenges: scaling up screening for at-risk individuals in stages 1–2, and speeding clinical trial recruitment and regulatory pathways so that effective therapies reach patients earlier and more widely.
Panel participants: Michael Haller, Professor of Pediatrics, University of Florida; Michelle Katz, Pediatric Endocrinologist, Eli Lilly; Monica Kumar, Senior Global Project Head, Sanofi; Anton Lindqvist, Chief Scientific Officer, Diamyd Medical. Moderated by Sanjoy Dutta, Ph.D., Breakthrough T1D’s Chief Scientific Officer.
|
November 14, 2025 Sweden
On the World Diabetes Day, November 14, Diamyd Medical hosted an expert panel on the future of type 1 diabetes treatment. The discussion explored: - How close the field is to modifying the course of type 1 diabetes rather than only managing its symptoms
- The impact of preserving endogenous insulin production on long-term stability and quality of life
- The convergence of immune tolerance and precision medicine in therapies such as Diamyd Medical’s GAD65-based approach
- How insights from earlier GAD studies are shaping the ongoing Phase 3 trial, with results expected around March 2026
Panel participants - Prof. Johnny Ludvigsson – pediatrician and T1D researcher, founder of Barndiabetesfonden and principal investigator in GAD/Diamyd® trials.
- Joshua Vieth, Breakthrough T1D – leads research strategy at a global T1D non-profit funding disease-modifying trials, including prevention.
- Prof. Åke Lernmark – T1D researcher focused on genetics, HLA and autoantibodies, central to understanding risk and prevention of the disease.
- Ulf Hannelius, CEO, Diamyd Medical. Diamyd Medical is developing a GAD65-based precision therapy (Diamyd®) to preserve the body’s own insulin production.
The webcast was produced by BioStock and moderated by Jonas Söderström.
|
November 3, 2025 USA
Ventures Accelerated summarizes how the 2025 Nobel Prize in Physiology or Medicine, awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for discoveries in peripheral immune tolerance, is now paving the way for new treatments for autoimmune and inflammatory diseases.
Through an interview with Nobel laureate Fred Ramsdell and examples from companies including Diamyd Medical, the article illustrates how decades of T-cell research are being translated into precision therapies and new investment opportunities in chronic inflammation and autoimmunity. The article also features Karin Rosén, a member of the board of directors of Diamyd Medical, who provides the company’s perspective on how these scientific breakthroughs connect to the development of antigen-specific treatments for type 1 diabetes. Read the article here
|